________
What is this all about?
Emergent is a biopharmaceutical company that develops vaccines and antibody therapies for infectious diseases. In response to the COVID-19 pandemic, Emergent signed deals with Johnson & Johnson and AstraZeneca worth a combined $875 million to provide services to produce those companies’ COVID-19 vaccine candidates, as well as another $628 million from the U.S. government as part of Operation Warp Speed. Emergent's executives stated that it had "proven manufacturing capabilities in place," rendering the Company "uniquely prepared to answer the call for [the] COVID-19 pandemic."
However, on March 31, 2021, news reports revealed that employees at Emergent's Baltimore manufacturing facility "mixed up" ingredients for the J&J and AstraZeneca vaccines, contaminating up to 15 million doses of the J&J vaccine. It was further revealed that this was not an isolated incident, but part of a history of manufacturing issues at the plant. News later broke that by December 2020, Emergent had to discard the equivalent of millions of AstraZeneca vaccine doses after they were spoiled by bacterial contamination at the same Baltimore plant. Shares plummeted over 15% in the next two trading days, down from the March 31, 2021 close of $92.91 per share to an April 5, 2021 close of $78.62 per share.
Please go to Global News Wire to read more.
Emergent Biosolutions Inc. manufactures vaccines (injections) for Johnson & Johnson:
Source: Global News Wire
May 25, 2021 08:00 ET | Source: Block & Leviton LLP
BOSTON, May 25, 2021 (GLOBE NEWSWIRE) -- Block & Leviton LLP announces that a lawsuit for violations of the federal securities laws has been filed against Emergent BioSolutions Inc. (NYSE: EBS) and certain of its executives. Investors who have lost money should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/ebs. The deadline to move for appointment as lead plaintiff is June 18, 2021.
May 25, 2021 08:00 ET | Source: Block & Leviton LLP
BOSTON, May 25, 2021 (GLOBE NEWSWIRE) -- Block & Leviton LLP announces that a lawsuit for violations of the federal securities laws has been filed against Emergent BioSolutions Inc. (NYSE: EBS) and certain of its executives. Investors who have lost money should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/ebs. The deadline to move for appointment as lead plaintiff is June 18, 2021.
What is this all about?
Emergent is a biopharmaceutical company that develops vaccines and antibody therapies for infectious diseases. In response to the COVID-19 pandemic, Emergent signed deals with Johnson & Johnson and AstraZeneca worth a combined $875 million to provide services to produce those companies’ COVID-19 vaccine candidates, as well as another $628 million from the U.S. government as part of Operation Warp Speed. Emergent's executives stated that it had "proven manufacturing capabilities in place," rendering the Company "uniquely prepared to answer the call for [the] COVID-19 pandemic."
However, on March 31, 2021, news reports revealed that employees at Emergent's Baltimore manufacturing facility "mixed up" ingredients for the J&J and AstraZeneca vaccines, contaminating up to 15 million doses of the J&J vaccine. It was further revealed that this was not an isolated incident, but part of a history of manufacturing issues at the plant. News later broke that by December 2020, Emergent had to discard the equivalent of millions of AstraZeneca vaccine doses after they were spoiled by bacterial contamination at the same Baltimore plant. Shares plummeted over 15% in the next two trading days, down from the March 31, 2021 close of $92.91 per share to an April 5, 2021 close of $78.62 per share.
Please go to Global News Wire to read more.
________
Emergent Biosolutions Inc. manufactures vaccines (injections) for Johnson & Johnson:
Related:
22-Year VAERS record (if the VAERS record is accurate):
This is getting too close to Anthony "gain of function" Fauci & Co.:
Listen to this pandemic biosecurity state techno jargon from Anthony "gain of function" Fauci and the "head of the hydra", Robert Kadlec discussing the biosecurity state and this Covid fake pandemic at the Council on Foreign Relations (CFR). By the way, contrary to the CFR moderator saying "the Chinese sequenced the gene virus," that is not correct. The Covid virus has not been isolated. If it has been isolated where is the proof? These people are laughing about "Chinese cooperation" (Biden's handlers shut down the Wuhan, China investigation) while the rest of us have been intentionally thrown into utter chaos. These people are building the global biosecurity state around Covid.
Ha ha ha...
Google blogger: Please don't censor this material.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.